Investors
PhaseBio Pharmaceuticals, Inc. raised $25 million in a Series B financing round on December 22, 2010. New investors New Enterprise Associates (NEA) and OSI Investment Management, a subsidiary of OSI Pharmaceuticals (OSI), led the round, with participation from existing investors Hatteras Venture Partners, Johnson & Johnson Development Corporation and Fletcher Spaght Ventures.